Market Cap 2.44M
Revenue (ttm) 780,000.00
Net Income (ttm) -5.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -725.64%
Debt to Equity Ratio 0.00
Volume 86,200
Avg Vol 1,092,120
Day's Range N/A - N/A
Shares Out 1.77M
Stochastic %K 16%
Beta 1.98
Analysts Strong Buy
Price Target N/A

Company Profile

Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome. In addition, the company markets its com...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 276 6888
Address:
47685 Lakeview Blvd., Fremont, United States
urgetosurge
urgetosurge Jan. 14 at 3:42 PM
$TIVC $6.5 on recent acquired discounted assets, just for the purchased equipment, with zero premium on anything else.
1 · Reply
urgetosurge
urgetosurge Jan. 14 at 3:31 PM
$TIVC 3.36 book value. Triple pimple without contracts. Intrinsic assets fair value discount at 50 million ish? Just a guess but why not if scratch start up is 80-100 million on assets fixtures.
0 · Reply
Nakuldesai
Nakuldesai Jan. 13 at 9:30 PM
$TIVC its game over here. Heading below 1.
0 · Reply
urgetosurge
urgetosurge Jan. 13 at 3:11 PM
$TIVC mms trolling for shares. Algos dujour. Nothing more.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 1:14 PM
$TIVC the tone of the cc was also noted. Assets weren't executed out of a hail Mary desperation no other option choice. Deliberate and pre stage contracts set up. They eliminated manufacturing security issues that Barda requires. Her confidence on becoming a multi billion dollar revenue operation was stellar. This isn't a flip trade instrument. This is a longer term investment instrument. A flip here will lose out on untapped market cap adjusted returns. Just my take.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 1:05 PM
$TIVC I'm actually shocked they acquired turn key assets at sub value pricing. Strategic and immediately accretive. That's rare, especially in the bio sector.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 12:55 PM
$TIVC the assets acquired at 16 million would have cost 80-100 million to possess from scratch. Furthermore eliminated manufacturing and production times, saving millions upon millions. Brilliant move on all metrics. 18 months deferred on financing payments from signing. Visionary and excellent execution. I think the markets will soon factor in the intrinsic assets from these levels. Just my take.
0 · Reply
Team_Zissou
Team_Zissou Jan. 12 at 10:10 PM
$TIVC Anyone else listen to the call? Very good background information on how the deal came together. She emphasized more than once that other CDMO’s would be a 12-24 month delay before Entolimod could be manufactured, in addition to more costly and less responsive. She talked about the CDMO landscape overall and how many underserved needs are out there, enabling Velocity to find customers and gain revenue. She also mentioned how beneficial securing the supply chain will be for future discussions. That said, the focus on scaling Entolimod is immediate and no other customers at this time. In addition she emphasized the BARDA meeting was a TechWatch only and not to expect any contracts coming out of it. My favorite part, which she repeated more than once, was the potential for Entolimod to be a multi-billion dollar asset. This company made a very focused, very strategic acquisition of a CDMO to help them advance Entolimod as fast as possible, while providing optionally down the road
4 · Reply
urgetosurge
urgetosurge Jan. 12 at 10:02 PM
$TIVC seldom is there a disproportionate reward to risk in the markets, especially at significant sub intrinsic valuation. At 3.4 MC, i doubt one could find a better opportunity than here. Just my take.
0 · Reply
urgetosurge
urgetosurge Jan. 12 at 7:33 PM
$TIVC 3.4 million market cap. Below intrinsic assets 5 fold.
0 · Reply
Latest News on TIVC
Tivic Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 2 months ago

Tivic Reports Third Quarter 2025 Financial Results


Tivic Expands Intellectual Property Portfolio

Nov 10, 2025, 9:00 AM EST - 2 months ago

Tivic Expands Intellectual Property Portfolio


Tivic Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:00 PM EDT - 5 months ago

Tivic Reports Second Quarter 2025 Financial Results


Tivic Health Announces 2025 Annual Meeting of Stockholders

Jun 24, 2025, 8:30 AM EDT - 7 months ago

Tivic Health Announces 2025 Annual Meeting of Stockholders


Tivic Expands VNS Intellectual Property Portfolio

May 13, 2025, 8:30 AM EDT - 8 months ago

Tivic Expands VNS Intellectual Property Portfolio


Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript

Mar 21, 2025, 6:32 PM EDT - 10 months ago

Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript


Tivic Health Systems, Inc. Announces Reverse Stock Split

Mar 5, 2025, 8:15 AM EST - 11 months ago

Tivic Health Systems, Inc. Announces Reverse Stock Split


CEO Letter to Shareholders Issued by Tivic Health

Dec 23, 2024, 4:54 PM EST - 1 year ago

CEO Letter to Shareholders Issued by Tivic Health


Tivic Health Accelerates VNS Commercial Strategy Development

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Tivic Health Accelerates VNS Commercial Strategy Development


Tivic Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Tivic Reports Second Quarter 2024 Financial Results


urgetosurge
urgetosurge Jan. 14 at 3:42 PM
$TIVC $6.5 on recent acquired discounted assets, just for the purchased equipment, with zero premium on anything else.
1 · Reply
urgetosurge
urgetosurge Jan. 14 at 3:31 PM
$TIVC 3.36 book value. Triple pimple without contracts. Intrinsic assets fair value discount at 50 million ish? Just a guess but why not if scratch start up is 80-100 million on assets fixtures.
0 · Reply
Nakuldesai
Nakuldesai Jan. 13 at 9:30 PM
$TIVC its game over here. Heading below 1.
0 · Reply
urgetosurge
urgetosurge Jan. 13 at 3:11 PM
$TIVC mms trolling for shares. Algos dujour. Nothing more.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 1:14 PM
$TIVC the tone of the cc was also noted. Assets weren't executed out of a hail Mary desperation no other option choice. Deliberate and pre stage contracts set up. They eliminated manufacturing security issues that Barda requires. Her confidence on becoming a multi billion dollar revenue operation was stellar. This isn't a flip trade instrument. This is a longer term investment instrument. A flip here will lose out on untapped market cap adjusted returns. Just my take.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 1:05 PM
$TIVC I'm actually shocked they acquired turn key assets at sub value pricing. Strategic and immediately accretive. That's rare, especially in the bio sector.
1 · Reply
urgetosurge
urgetosurge Jan. 13 at 12:55 PM
$TIVC the assets acquired at 16 million would have cost 80-100 million to possess from scratch. Furthermore eliminated manufacturing and production times, saving millions upon millions. Brilliant move on all metrics. 18 months deferred on financing payments from signing. Visionary and excellent execution. I think the markets will soon factor in the intrinsic assets from these levels. Just my take.
0 · Reply
Team_Zissou
Team_Zissou Jan. 12 at 10:10 PM
$TIVC Anyone else listen to the call? Very good background information on how the deal came together. She emphasized more than once that other CDMO’s would be a 12-24 month delay before Entolimod could be manufactured, in addition to more costly and less responsive. She talked about the CDMO landscape overall and how many underserved needs are out there, enabling Velocity to find customers and gain revenue. She also mentioned how beneficial securing the supply chain will be for future discussions. That said, the focus on scaling Entolimod is immediate and no other customers at this time. In addition she emphasized the BARDA meeting was a TechWatch only and not to expect any contracts coming out of it. My favorite part, which she repeated more than once, was the potential for Entolimod to be a multi-billion dollar asset. This company made a very focused, very strategic acquisition of a CDMO to help them advance Entolimod as fast as possible, while providing optionally down the road
4 · Reply
urgetosurge
urgetosurge Jan. 12 at 10:02 PM
$TIVC seldom is there a disproportionate reward to risk in the markets, especially at significant sub intrinsic valuation. At 3.4 MC, i doubt one could find a better opportunity than here. Just my take.
0 · Reply
urgetosurge
urgetosurge Jan. 12 at 7:33 PM
$TIVC 3.4 million market cap. Below intrinsic assets 5 fold.
0 · Reply
Team_Zissou
Team_Zissou Jan. 12 at 3:55 PM
$TIVC What I’m looking for this afternoon: • Quantify the CDMO pipeline (customer count, LOIs, expected first revenue timing) • Give a tighter BLA filing timeline (post‑200L cGMP?) • Reaffirm BARDA meeting to take place on 26 Jan • Hints at reducing preferred/equity line reliance based on Velocity savings
0 · Reply
Team_Zissou
Team_Zissou Jan. 12 at 3:37 PM
$TIVC Anyone else catch this particular line from the CEO? Potential acquisition… Also, 3 weeks in between the BARDA meeting and shareholder meeting on 19 Feb. Plenty of time to build a case for shareholders to approve the dilution because of positive catalysts from BARDA “…reinforcing our strategy to advance Entolimod as a priority therapeutic asset for government partnership or potential acquisition."
0 · Reply
urgetosurge
urgetosurge Jan. 12 at 2:39 PM
$TIVC billions in contracts and the ability to deliver. Market cap is sub valued beyond the pale. Just my take.
0 · Reply
urgetosurge
urgetosurge Jan. 12 at 2:19 PM
$TIVC Barda this month. Everything's all set.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:19 PM
$TIVC 09:03 on Jan. 12 2026 Tivic Health Systems Delivers 200x Scale-Up In Manufacturing Volume For Lead Drug Candidate Entolimod #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:08 PM
$TIVC 09:03 on Jan. 12 2026 Tivic Health Systems Delivers 200x Scale-Up In Manufacturing Volume For Lead Drug Candidate Entolimod #tradeideas
0 · Reply
chanimalll
chanimalll Jan. 12 at 2:03 PM
0 · Reply
chanimalll
chanimalll Jan. 12 at 2:01 PM
$TIVC news 🫶
0 · Reply
Team_Zissou
Team_Zissou Jan. 9 at 10:50 PM
$TIVC I missed the exchange cap in my initial look at the financing. Posting for all. AI Exchange Cap Analysis: Protected Period Through March 2026 The Baseline Numbers (December 9, 2025) From the 8-K filing, the Exchange Cap is calculated as 19.99% of outstanding shares on December 9, 2025. The 8-K states: “The Exchange Cap [is] 19.99% of the outstanding number of shares of Common Stock at the time the Company entered into the Note Purchase Agreement and Preferred Purchase Agreement, or 353,013 shares” Working backwards: 353,013 ÷ 0.1999 = 1,766,568 shares outstanding on December 9, 2025 What the Exchange Cap Actually Limits The 8-K is crystal clear: “If the Note was to fully convert (including interest and the Make-Whole Amount) into Conversion Shares at the Conversion Price, assuming no Exchange Cap, the Company would issue 9,106,425 Conversion Shares.” But they CAN’T issue anywhere near that many shares until shareholders approve waiving the Exchange Cap (expected in March)
2 · Reply
chanimalll
chanimalll Jan. 9 at 3:56 PM
$TIVC heavy Bid Stacking come on!! New Monday with the meeting. Low float, nothing else running crazy to steal volume. I see a good set up🚀
1 · Reply
urgetosurge
urgetosurge Jan. 8 at 2:55 PM
$TIVC until technicals and diluting abate, looks like ongoing pump to dump. Not questioning the intrinsic value of their assets and portfolio, but rather fiduciary investor roi. I have yet to see anything other than systematic rug pulls. Just my take.
0 · Reply
urgetosurge
urgetosurge Jan. 8 at 2:22 PM
$TIVC S3 forms filed in advance. Need to see a fiduciary roi firming here. We also need share update.
0 · Reply